Common use of Results Reporting Clause in Contracts

Results Reporting. Contractor shall: a. Complete all negative specimen analyses (not requiring GC/MS) and report results of the drug panel to the designated MRO within 48 hours of the receipt of the tested specimen in the laboratory. All other non-negative analyses must be completed in a time frame consistent with DOT/DHHS regulations. b. Assure that all test results - including the initial results, confirmation, and quality control date - are reviewed by the Contractor’s Laboratory Director or a supervisory scientist before being certified as accurate. c. Transmit a standardized written report of all test results performed to the designated Medical Review Officer in a timely manner on the same day that the certifying scientist completes the review. The written report shall be in a format approved by the SFMTA and its MRO. d. Submit together in batch form only specimens marked “random testing” or “follow up” from collection site to laboratory, and from laboratory to MRO. All others shall be submitted individually. e. Identify in the results report, the drugs or their metabolites tested, whether positive or negative, the cutoff level for each, the identification number assigned by the member and the drug testing laboratory specimen identification number. The analytical results shall not be expressed in equivocal terms such as “possible,” “traces,” or “+.” f. Report as negative all specimens which are negative on the initial test or negative on the confirmatory test. Only specimens confirmed positive, adulterated, or substituted at or above the specified cutoff levels shall be reported positive for a specific drug or drug metabolite. Specimens confirmed to be adulterated or substituted in accordance with 49 CFR Part 40 subpart F will be reported as such. g. Contractor shall transmit the original or certified true copy of the urine custody and control form signed by the person responsible for the day-to-day management of the Contractor’s laboratory and the test report. This report shall be electronically transmitted to the MRO in a manner designed to ensure the confidentiality of the information. h. Retain all records pertaining to a given urine specimen in secure storage for a period of two years and make them available to the SFMTA for audit purposes. i. Upon request, make available to the MRO or Substance Abuse Professional (SAP) any quantification of test results.

Results Reporting. Contractor shall: a. Complete all negative specimen analyses (not requiring GC/MS) and report results of the drug panel to the designated MRO within 48 hours of the receipt of the tested specimen in the laboratory. All other non-negative analyses must be completed in a time frame consistent with DOT/DHHS regulations. b. Assure that all test results - including the initial results, confirmation, and quality control date - are reviewed by the Contractor’s Laboratory Director or a supervisory scientist before being certified as accurate. c. Transmit a standardized written report of all test results performed to the designated Medical Review Officer in a timely manner on the same day that the certifying scientist completes the review. The written report shall be in a format approved by the SFMTA and its MRO. d. Submit together in batch form only specimens marked “random testing” or “follow uppre- employment testing” from collection site to laboratory, and from laboratory to MRO. All others shall be submitted individually. e. Identify in the results report, the drugs or their metabolites tested, whether positive or negative, the cutoff level for each, the identification number assigned by the member and the drug testing laboratory specimen identification number. The analytical results shall not be expressed in equivocal terms such as “possible,” “traces,” or “+.” f. Report as negative all specimens which are negative on the initial test or negative on the confirmatory test. Only specimens confirmed positive, adulterated, or substituted at or above the specified cutoff levels shall be reported positive for a specific drug or drug metabolite. Specimens confirmed to be adulterated or substituted in accordance with 49 CFR Part 40 subpart F will be reported as such. g. Contractor shall transmit the original or certified true copy of the urine custody and control form signed by the person responsible for the day-to-day management of the Contractor’s laboratory and the test report. This report shall be electronically transmitted to the MRO in a manner designed to ensure the confidentiality of the information. h. Retain all records pertaining to a given urine specimen in secure storage for a period of two years and make them available to the SFMTA for audit purposes. i. Upon request, make available to the MRO or Substance Abuse Professional (SAP) any quantification of test results.